PMID- 17289327
OWN - NLM
STAT- MEDLINE
DCOM- 20070622
LR  - 20221207
IS  - 0731-7085 (Print)
IS  - 0731-7085 (Linking)
VI  - 44
IP  - 1
DP  - 2007 May 9
TI  - Simultaneous and rapid quantitation of benazepril and benazeprilat in human 
      plasma by high performance liquid chromatography with ultraviolet detection.
PG  - 224-30
AB  - A sensitive and accurate high-performance liquid chromatography (HPLC) method 
      with ultraviolet (UV) detector was developed and validated for simultaneous 
      determination of benazepril (BZL) and its active metabolite, benazeprilat (BZT), 
      in human plasma. The plasma sample, after spiked with riluzole as an internal 
      standard (IS), was subjected to a solid-phase extraction (SPE) prior to a HPLC 
      analysis. Chromatographic separations were achieved on a Hypersil BDS C(18) (300 
      mm x 4.6mm, 5 microm). The mobile phase consisted of phosphate buffer (pH 2.6; 
      10mM) and acetonitrile mixture in a gradient mode. Detection was carried out at a 
      wavelength of 237 nm. The retention times of BZL, BZT and IS were at about 6.2, 
      15.4 and 16.2 min, respectively. The calibration curve was linear in the range of 
      20-2000 ng/mL for both BZL and BZT (r(2)>0.997). At three quality control 
      concentrations of 100, 500, and 1500 ng/mL, the intra-day and inter-day relative 
      standard deviation ranged from 2.8 to 8.6% for BZL and from 2.2 to 8.5% for BZT, 
      while the mean absolute percentage error ranged from -7.5 to 6.7% for BZL and 
      from -6.0 to 3.2% for BZT. The limit of detection (LOD) was 10 ng/mL and the 
      limit of quantification (LOQ) was 20 ng/mL for both BZL and BZT in human plasma. 
      The method was successfully applied to bioequivalence evaluation of benazepril 
      hydrochloride formulations in healthy Chinese.
FAU - Wang, Xue-Ding
AU  - Wang XD
AD  - Institute of Clinical Pharmacology, School of Pharmaceutical Sciences, Sun 
      Yat-sen University, Guangzhou, China.
FAU - Chan, Eli
AU  - Chan E
FAU - Chen, Xiao
AU  - Chen X
FAU - Liao, Xiao-Xing
AU  - Liao XX
FAU - Tang, Cheng
AU  - Tang C
FAU - Zhou, Zhi-Wei
AU  - Zhou ZW
FAU - Huang, Min
AU  - Huang M
FAU - Zhou, Shu-Feng
AU  - Zhou SF
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20070117
PL  - England
TA  - J Pharm Biomed Anal
JT  - Journal of pharmaceutical and biomedical analysis
JID - 8309336
RN  - 0 (Acetonitriles)
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
RN  - 0 (Benzazepines)
RN  - 0 (Buffers)
RN  - 0 (Phosphates)
RN  - 0 (Tablets)
RN  - 7LJ087RS6F (Riluzole)
RN  - JRM708L703 (benazeprilat)
RN  - UDM7Q7QWP8 (benazepril)
RN  - Z072SB282N (acetonitrile)
SB  - IM
MH  - Acetonitriles/chemistry
MH  - Administration, Oral
MH  - Angiotensin-Converting Enzyme Inhibitors/administration & 
      dosage/*blood/chemistry/pharmacokinetics
MH  - Area Under Curve
MH  - Asian People
MH  - Benzazepines/administration & dosage/*blood/chemistry/pharmacokinetics
MH  - Buffers
MH  - Calibration
MH  - Chemistry, Pharmaceutical
MH  - Chromatography, High Pressure Liquid/instrumentation/*methods
MH  - Drug Stability
MH  - Freezing
MH  - Humans
MH  - Hydrogen-Ion Concentration
MH  - Male
MH  - Molecular Structure
MH  - Phosphates/chemistry
MH  - Reference Standards
MH  - Reproducibility of Results
MH  - Riluzole
MH  - Sensitivity and Specificity
MH  - Solid Phase Extraction
MH  - Spectrophotometry, Ultraviolet/*methods
MH  - Tablets
MH  - Temperature
MH  - Therapeutic Equivalency
MH  - Time Factors
EDAT- 2007/02/10 09:00
MHDA- 2007/06/23 09:00
CRDT- 2007/02/10 09:00
PHST- 2006/09/26 00:00 [received]
PHST- 2007/01/06 00:00 [revised]
PHST- 2007/01/10 00:00 [accepted]
PHST- 2007/02/10 09:00 [pubmed]
PHST- 2007/06/23 09:00 [medline]
PHST- 2007/02/10 09:00 [entrez]
AID - S0731-7085(07)00036-2 [pii]
AID - 10.1016/j.jpba.2007.01.009 [doi]
PST - ppublish
SO  - J Pharm Biomed Anal. 2007 May 9;44(1):224-30. doi: 10.1016/j.jpba.2007.01.009. 
      Epub 2007 Jan 17.